| 000 | 01771 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250513091932.0 | ||
| 264 | 0 | _c19960807 | |
| 008 | 199608s 0 0 eng d | ||
| 022 | _a0027-8874 | ||
| 024 | 7 |
_a10.1093/jnci/88.14.956 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWang, Q | |
| 245 | 0 | 0 |
_aUCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. _h[electronic resource] |
| 260 |
_bJournal of the National Cancer Institute _cJul 1996 |
||
| 300 |
_a956-65 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAlkaloids _xpharmacology |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 |
_aBurkitt Lymphoma _xdrug therapy |
| 650 | 0 | 4 |
_aCDC2 Protein Kinase _xdrug effects |
| 650 | 0 | 4 |
_aCell Division _xdrug effects |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 |
_aCisplatin _xpharmacology |
| 650 | 0 | 4 |
_aColonic Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aCyclin B |
| 650 | 0 | 4 | _aCyclin B1 |
| 650 | 0 | 4 |
_aCyclins _xdrug effects |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 | _aFlow Cytometry |
| 650 | 0 | 4 |
_aG2 Phase _xdrug effects |
| 650 | 0 | 4 | _aGamma Rays |
| 650 | 0 | 4 |
_aGenes, p53 _xgenetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunoblotting |
| 650 | 0 | 4 | _aMitotic Index |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 | _aPrecipitin Tests |
| 650 | 0 | 4 | _aRadiation Dosage |
| 650 | 0 | 4 |
_aStaurosporine _xanalogs & derivatives |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 700 | 1 | _aFan, S | |
| 700 | 1 | _aEastman, A | |
| 700 | 1 | _aWorland, P J | |
| 700 | 1 | _aSausville, E A | |
| 700 | 1 | _aO'Connor, P M | |
| 773 | 0 |
_tJournal of the National Cancer Institute _gvol. 88 _gno. 14 _gp. 956-65 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/jnci/88.14.956 _zAvailable from publisher's website |
| 999 |
_c8665732 _d8665732 |
||